With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.6859-99-0,Piperidin-3-ol,as a common compound, the synthetic route is as follows.
6859-99-0, A solution of di-tert-butyl dicarbonate (5.83 g, 26.7 mmol) in dichloromethane (10 ml) was added to a solution of 3-hydroxypiperidine (3.0 g, 29.7 mmol) in dichloromethane (30 ml) at room temperature and stirred for 15 hours. The reaction solution was concentrated, diluted with ethyl acetate, and then washed with a saturated aqueous sodium hydrogencarbonate solution, a 0.5M-aqueous potassium hydrogensulfate solution, a saturated aqueous sodium hydrogencarbonate solution and then a saturated aqueous sodium chloride solution. The organic layer was dried over anhydrous magnesium sulfate and distilled under reduced pressure to remove the solvent, and the resulting residue was crystallized by the addition of hexane, filtered, and then dried to obtain tert-butyl 3-hydroxy-1-piperidinecarboxylate (5.17 g, 87percent).1H-NMR (DMSO-d6) delta; 1.46 (9H, s, 1.99 (2H, m), 3.34-3.49 (4H, m), 4.45 (1H, m).
The synthetic route of 6859-99-0 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; Sumitomo Pharmaceuticals Company, Limited; EP1403255; (2004); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem